Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2025
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
10 October 2025 - Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them ...
Posted by Michael Wonder on 09 Oct 2025
Why the Government must urgently raise the NICE cost effectiveness threshold
7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...
Posted by Michael Wonder on 08 Oct 2025
Britain prepares NHS drug spending hike to stave off Trump tariffs
8 October 2025 - The UK Government has drawn up proposals to increase the amount the National Health Service pays ...
Posted by Michael Wonder on 08 Oct 2025
Ontario connecting patients to life-saving cancer drugs faster
7 October 2025 - The Ontario Government is leading the world in cancer care by launching the Funding Accelerated for ...
Posted by Michael Wonder on 04 Oct 2025
Andexanet alfa for haemorrhage: hope not fulfilled
1 October 2025 - A comparative study conducted at the instigation of the EMA shows only negative effects. ...
Posted by Michael Wonder on 03 Oct 2025
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price
22 September 2025 - Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. ...
Posted by Michael Wonder on 02 Oct 2025
PHARMAC proposes changes to make it easier to access HIV medicines
1 October 2025 - New Zealanders living with, or at risk of, HIV could soon benefit from proposed changes to ...
Posted by Michael Wonder on 01 Oct 2025
New Zealand Pharmaceutical Schedule - 1 October 2025
1 October 2025 - The October 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2025
Schedule of Pharmaceutical Benefits - 1 October 2025
1 October 2025 - The October 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Sep 2025
AbbVie announces UK pricing strategy for Elahere (mirvetuximab soravtansine-gynx)
29 September 2025 - The list price will be consistent with the US to reflect the value of the innovation. ...
Posted by Michael Wonder on 29 Sep 2025
New life changing medicines listed on the PBS
28 September 2025 - From 1 October 2025, Australians affected by breast cancer and rare kidney disease will have access ...
Posted by Michael Wonder on 27 Sep 2025
Major breast cancer treatment cost slashed under new PBS listing
28 September 2025 - Thousands of women will pay significantly less for treatment after the Federal Government listed a leading ...
Posted by Michael Wonder on 27 Sep 2025
Health Minister Mark Butler says PBS not for negotiation, Donald Trump announced 100 pc tariff on pharmaceutical goods
26 September 2025 - Health Minister Mark Butler says Australia’s PBS will be protected at all costs, despite a pending ...
Posted by Michael Wonder on 24 Sep 2025
PHARMAC proposes funding five medicines and more convenient treatment options to ease pressure on health services
24 September 2025 - New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer could benefit from ...
Posted by Michael Wonder on 24 Sep 2025
New subcutaneous formulation of Opdivo receives positive INESSS recommendation for multiple tumour types
23 September 2025 - Milestone decision recognises the value of SC formulation of Opdivo to help support delivery flexibility ...